This is a paid press release. Contact the press release distributor directly with any inquiries.
Secretome Therapeutics Expands Rare Disease Leadership Team
Business Wire
Tue, July 28, 2026 at 12:00 AM GMT+5:30
4 min read
PLANO, Texas, July 27, 2026–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The Company also announced that Dr. Marshelle Smith, M.D., has transitioned into the role of Chief Development Officer.
“Secretome is evolving into a premier, rare disease-focused biopharma company, and each of the senior leaders joining our team has deep experience building world-class drug development organizations focused on rare diseases,” said Vinny Jindal, Co-Founder and Chief Executive Officer of Secretome Therapeutics. “With our leadership team in place, we are well-positioned to advance STM-01 into late-stage clinical studies for Duchenne muscular dystrophy (DMD), and to continue maturing our platform of novel regenerative therapies for a broad array of rare and underserved diseases.”
Dr. Singh joins Secretome as Chief Medical Officer with more than three decades of experience in clinical development, regulatory strategy, and rare disease drug development. Most recently, he led clinical development at Sarepta Therapeutics, where he oversaw programs focused on advancing innovative therapies. Prior to Sarepta, he held positions of increasing responsibility in cell and gene therapy development at Sanofi/Genzyme. Throughout his career, Dr. Singh has successfully advanced therapies from early-stage development through regulatory approval and has contributed to multiple product approvals.
As Senior Vice President of Operations, David Chapman will build commercial and operational infrastructure to support the growth and maturation of Secretome’s development programs and the company at-large. He brings more than 30 years of leadership experience in the US and Europe across commercial strategy, market access, product launch, and organizational buildout, including senior executive and commercial roles at Zambon USA, Agios Pharmaceuticals, AMAG/COVIS, Reata Pharmaceuticals, Boehringer Ingelheim, and Pfizer. His experience spans more than 20 product launches across rare disease, hematology, pulmonary, cardiovascular, neurology, and other specialty therapeutic areas, as well as business development, alliance management, and government affairs.
